Publications

Small cell-like glandular proliferation of prostate: A rare lesion not related to small cell prostate cancer

Virchows Arch. 2017 Jan;470(1):47-54

Kryvenko ON, Williamson SR, Trpkov K, Gupta NS, Athanazio D, Selig MK, Smith PT, Magi-Galluzzi C, Jorda M

Abstract

Small cell-like change (SCLC) is a rare prostate lesion which has been described in only two previous studies (total of eight cases). Its relation to possible neuroendocrine differentiation remained unclear. We evaluated 11 SCLC cases with immunohistochemistry and electron microscopy. SCLC was characterized by crowded hyperchromatic small nuclei with scant cytoplasm, rosette-like structures, finely granular chromatin with indistinct nucleoli, and lack of mitoses, apoptoses, and necroses. In nine cases, SCLC was admixed with high-grade cancer, and in two cases, it represented a separate intraductal process, spatially remote from a low-volume Gleason score 6 (grade group 1) cancer. Only 2/11 SCLC labeled for synaptophysin, chromogranin, and serotonin, although 6/11 were at least focally positive for TTF1. Staining for NKX3.1 and pancytokeratin was typically weak, focal, and markedly reduced compared to the adjacent cancer. SCLC was positive for ERG in 1/8 and for racemase in 6/10 cases, again typically in a focal and weak fashion. There was no immunoreactivity with CD56, p63, or HMWCK. Ki-67 highlighted only rare nuclei (<1 %). No neuroendocrine granules were demonstrated by electron microscopy in four cases that showed no immunoreactivity for neuroendocrine markers. In summary, SCLC is more frequently found in high-grade prostate cancer, but it may also be encountered as a noninvasive lesion in Gleason score 6 (grade group 1) cancer. Importantly, it does not appear to indicate neuroendocrine differentiation. The low-grade cytology, the lack of mitoses and apoptoses, and the minimal Ki-67 reactivity are findings to support its discrimination from a small cell carcinoma.

PubMed

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

The Alberta Prostate Cancer Biorepository is certified by CTRNet

APCaRI is committed to collecting, processing and storing the samples you donate with the highest quality standards and as a result, after evaluation of our processes, the CTRNet (Canadian Tissue Repository Network) awarded us with their certification.

CTRNet is a translational cancer research resource, funded by Canadian Institutes of Health Research, that furthers Canadian health research by linking cancer researchers with provincial tumour banks.

The benefits of working with CTRNet include:

  • The ability for researchers to search for quality controlled tissue samples from Canada’s leading tumour banks in one central location and for biobanks to display and make their biospecimens available for research users.
  • Learning opportunities in tissue handling, research design and relevant technology training and innovations.
  • Invitation to CTRNet workshops and conferences.
- Catalina Vasquez